- Home
- DCGO vs TBPH Comparison
DCGO vs TBPH Comparison
Compare DCGO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- TBPH
- Stock Information
- Founded
- DCGO 2015
- TBPH 2013
- Country
- DCGO United States
- TBPH United States
- Employees
- DCGO N/A
- TBPH N/A
- Industry
- DCGO Managed Health Care
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- DCGO Health Care
- TBPH Health Care
- Exchange
- DCGO Nasdaq
- TBPH Nasdaq
- Market Cap
- DCGO 417.4M
- TBPH 418.7M
- IPO Year
- DCGO N/A
- TBPH N/A
- Fundamental
- Price
- DCGO $4.12
- TBPH $9.61
- Analyst Decision
- DCGO Strong Buy
- TBPH Buy
- Analyst Count
- DCGO 5
- TBPH 4
- Target Price
- DCGO $6.10
- TBPH $13.75
- AVG Volume (30 Days)
- DCGO 730.0K
- TBPH 200.9K
- Earning Date
- DCGO 11-07-2024
- TBPH 11-12-2024
- Dividend Yield
- DCGO N/A
- TBPH N/A
- EPS Growth
- DCGO 300.38
- TBPH N/A
- EPS
- DCGO 0.29
- TBPH N/A
- Revenue
- DCGO $694,968,328.00
- TBPH $63,192,000.00
- Revenue This Year
- DCGO $1.17
- TBPH $6.93
- Revenue Next Year
- DCGO N/A
- TBPH $45.31
- P/E Ratio
- DCGO $14.44
- TBPH N/A
- Revenue Growth
- DCGO 30.19
- TBPH 15.93
- 52 Week Low
- DCGO $2.75
- TBPH $7.44
- 52 Week High
- DCGO $6.21
- TBPH $11.71
- Technical
- Relative Strength Index (RSI)
- DCGO 65.99
- TBPH 62.56
- Support Level
- DCGO $3.84
- TBPH $9.38
- Resistance Level
- DCGO $4.43
- TBPH $10.10
- Average True Range (ATR)
- DCGO 0.26
- TBPH 0.33
- MACD
- DCGO 0.02
- TBPH 0.09
- Stochastic Oscillator
- DCGO 71.63
- TBPH 69.35
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).